Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma

Table 3 Results of survival analyses related to α-fetoprotein response

Author	Year	Overall survival			Progression-free survival
		HR	95%CI	P value	HR	95%CI	P value
Chen et al[21]	2005	0.242	0.10-0.61	0.003	-	-	-
Chan et al[20]	2009	0.412	0.27-0.63	0.0001	-	-	-
Riaz et al[27]	2009	0.3712	0.13-1.011	0.0002	-	-	-
Vora et al[29]	2009	0.952	0.73-1.231	0.88	0.482	0.15-1.451	0.09
Shao et al[28]	2010	0.362	0.15-0.83	0.017	0.312	0.14-0.67	0.003
Kim et al[23]	2011	0.432	0.29-0.65	0.001	0.482	0.33-0.70	0.001
Yau et al[30]	2011	0.32	0.09-1.02	0.05	0.312	0.13-0.76	0.01
Kao et al[22]	2012	0.1812	0.02-1.67	0.023	-	-	-
Lee et al[24]	2012/H	0.432	0.23-0.81	0.009	0.672	0.35-1.27	0.22
Lee et al[24]	2012/C	0.332	0.15-0.75	0.008	0.972	0.42-2.25	0.97
Memon et al[25]	2012	0.142	0.02-0.83	0.03	-	-	-
Personeni et al[26]	2012	0.522	0.31-0.85	0.009	-	-	-

¹Calculated result from data presented in article;

²Multivariate result; -: Not performed; 2012/H: Hepatic arterial infusional chemotherapy study; 2012/C: Concurrent chemoradiation therapy study; HR: Hazard ratio; AFP: α-fetoprotein.